Literature DB >> 18246127

Mutant B-RAF mediates resistance to anoikis via Bad and Bim.

K Boisvert-Adamo1, A E Aplin.   

Abstract

Normal cells undergo anoikis when they lose adhesion to or encounter an inappropriate extracellular matrix. By contrast, oncogenic signaling in tumor cells enables resistance to anoikis, a trait that contributes to tumor progression. The B-RAF serine-threonine kinase is mutated in multiple cancers and functions as an oncogene in melanoma. Previously, we demonstrated that B-RAF and downstream mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling are necessary for protection from anoikis in mutant B-RAF-expressing melanoma cells. Regulation of Bcl-2 family members in melanoma and their role in B-RAF-mediated survival is poorly defined. Here, we provide evidence that B-RAF-MEK signaling protects against anoikis through alterations in two proapoptotic Bcl-2 family proteins: Bcl-xL/Bcl-2-associated death promoter (Bad) and Bcl-2-interacting mediator of cell death (Bim). B-RAF-MEK signaling regulates phosphorylation of the inhibitory serine-75 residue of Bad, and decreases Bad mRNA expression. RNA interference and overexpression experiments demonstrate that Bad contributes to the susceptibility of B-RAF-depleted cells to anoikis. Additionally, B-RAF-MEK signaling regulates the expression of Bim(EL), mainly through control of protein turnover. Increased Bim(EL) levels induce apoptosis in suspended cells and are required for anoikis in B-RAF-depleted cells. Depletion of Bim together with Bad has an additive effect on protecting B-RAF knockdown cells from anoikis. Together, our data show that Bad and Bim are major B-RAF responsive proteins regulating apoptosis in melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246127     DOI: 10.1038/sj.onc.1211003

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

2.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Authors:  Yongping Shao; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.

Authors:  Manali S Phadke; Patrizia Sini; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2015-04-14       Impact factor: 6.261

4.  A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

Authors:  Junegoo Lee; Tilahun Jiffar; Michael E Kupferman
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

5.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 6.  Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression.

Authors:  Cassandra L Buchheit; Kelsey J Weigel; Zachary T Schafer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

7.  Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.

Authors:  Kevin J Basile; Andrew E Aplin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

8.  Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

Authors:  H Eirik Haarberg; Kim H T Paraiso; Elizabeth Wood; Vito W Rebecca; Vernon K Sondak; John M Koomen; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2013-03-28       Impact factor: 6.261

Review 9.  NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Authors:  I V Fedorenko; G T Gibney; K S M Smalley
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

10.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Authors:  Jonas N Søndergaard; Ramin Nazarian; Qi Wang; Deliang Guo; Teli Hsueh; Stephen Mok; Hooman Sazegar; Laura E MacConaill; Jordi G Barretina; Sarah M Kehoe; Narsis Attar; Erika von Euw; Jonathan E Zuckerman; Bartosz Chmielowski; Begoña Comin-Anduix; Richard C Koya; Paul S Mischel; Roger S Lo; Antoni Ribas
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.